- Annexon Announces Proposed Public Offering of Common Stock
- Annexon Announces Positive Topline Results from Pivotal Phase 3 Trial for First-in-Class C1q Blocking Antibody ANX005 in Guillain-Barré Syndrome
- Annexon Biosciences to Host Conference Call and Webcast to Discuss GBS Phase 3 Data
- Annexon Reports Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4)
- Annexon Reports First Quarter 2024 Financial Results and Key Anticipated Milestones
- Annexon Biosciences to Present at the Bank of America Health Care Conference
- Annexon Presents New Neuroprotection Data Showing ANX007 Protects Vision and Vision-Associated Structures in Geographic Atrophy at ARVO 2024 Annual Meeting
- Annexon to Present Data Reinforcing the Neuroprotective Effects of ANX007 and C1q Inhibition in Geographic Atrophy at the ARVO 2024 Annual Meeting
- Annexon Biosciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
- Annexon Reports Fourth Quarter and Year-End 2023 Financial Results and Key Anticipated Milestones
More ▼
Key statistics
As of last trade Annexon Inc (ANNX:NSQ) traded at 6.77, -19.46% below its 52-week high of 8.40, set on Mar 27, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 5.90 |
---|---|
High | 6.83 |
Low | 5.68 |
Bid | 6.76 |
Offer | 6.78 |
Previous close | 5.99 |
Average volume | 6.63m |
---|---|
Shares outstanding | 92.41m |
Free float | 84.60m |
P/E (TTM) | -- |
Market cap | 446.35m USD |
EPS (TTM) | -1.46 USD |
Data delayed at least 15 minutes, as of Jun 05 2024 16:39 BST.
More ▼